This innovative strategy aims to specifically restore p53 function in CRC cells, reverse the immunosuppressive microenvironment, enhance antitumor immune responses, and inhibit tumor growth, providing novel insights for improving CRC immunotherapy efficacy with significant clinical translation potential for combination therapy with immune checkpoint inhibitors. This evidence concerns the gene TP53 and colorectal carcinoma.